Advances in treatment of metastatic colorectal cancer with BRAF gene mutation
10.3760/cma.j.issn.1008-6315.2019.03.018
- VernacularTitle:BRAF基因突变型转移性结直肠癌的治疗进展
- Author:
Jiaqi FU
1
Author Information
1. 浙江大学医学院
- Keywords:
V-raf murine sarcoma viral oncogene homolog B;
Epidermal growth factor receptor;
Metastatic colorectal cancer;
Targeted therapy
- From:
Clinical Medicine of China
2019;35(3):272-275
- CountryChina
- Language:Chinese
-
Abstract:
Objective V-raf murine sarcoma virus oncogene homologous gene B (BRAF) gene plays an important role in mitogen-activated protein kinase signaling pathway by encoding RAF family serine/ threonine protein kinase.Mutations in the BRAF gene can lead to tumorigenesis.About 10％ of metastatic colorectal cancers have BRAF gene mutations.The prognosis of this type of cancer is poor,with a median overall survival of 12 months.Recent studies have shown that FOLFOXIRI regimen combined with bevacizumab can be used as a first-line treatment.In addition,simultaneous targeting inhibition of multiple signaling pathways can bring survival benefits to these patients.
